Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today highlighted its comprehensive range of specialty diagnostics products at the annual conference of the American Association for Clinical Chemistry (AACC). The company continued its focus on helping customers to improve productivity by introducing products that drive innovation in the clinical laboratory, from sample collection and storage to new immunoassays and quality controls. A number of new products are being showcased at Thermo Scientific booth 2215 during the Clinical Lab Expo at the AACC conference, being held at the Los Angeles Convention Center from July 17-19. “Healthcare professionals increasingly rely on new diagnostic tools to provide the information they need to make critical decisions involving patient care,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Our growing offering of specialty diagnostics enables physicians to make faster, more accurate diagnoses with the goal of improving patient outcomes.” Solutions to Improve Productivity in the Clinical Laboratory Thermo Fisher announced that its new Thermo Scientific QMS™ Tacrolimus immunoassay has been CE marked for sale in the European Union. The liquid, ready-to-use immunoassay provides bar-coded reagents to run on the Thermo Scientific Indiko bench-top chemistry analyzer. The product is not yet available for sale in the United States. The company also introduced a new generation of its Indiko platform, the Thermo Scientific Indiko® Plus® analyzer. Featuring the same compact design as its predecessor, the Indiko Plus analyzer is designed to deliver higher throughput for routine clinical research applications, including drugs-of-abuse testing and therapeutic drug monitoring. In addition, Thermo Fisher introduced immunoassay and chemistry controls that improve the clinical laboratory workflow by concentrating the number of analytes in a single vial. The new Thermo Scientific MAS Omni·CORE™ control consolidates general chemistry and serum protein quality control (QC) processing into a single solution that offers different levels of testing to streamline the workflow and reduce cost. The company’s new Thermo Scientific MAS Omni·Immune™ immunoassay control consolidates routine immunoassay, tumor marker and specialty immunoassay QC processing. Leading Portfolio of Immunodiagnostics for Improved Patient Care Thermo Fisher continues to expand its extensive capabilities in the clinical diagnosis and monitoring of allergies, asthma and autoimmune diseases by introducing several new assays at AACC. The Thermo Scientific EliA™ Rheumatoid Factor Assays, cleared by the FDA in Nov. 2011, provides clinicians with a reliable and simple tool to aid in the early diagnosis of rheumatoid arthritis. In addition, Thermo Scientific ImmunoCAP™ Tryptase Assay, cleared by the FDA in Feb. 2012, measures levels of a specific enzyme in serum or plasma to provides an earlier indication of systemic mastocytosis, a rare blood disorder. For more information on Thermo Fisher’s specialty diagnostics products being highlighted at AACC, please visit Thermo Scientific booth 2215 or visit the online media room at www.thermofisher.com/news. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com. The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general worldwide economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; the effect of healthcare reform legislation; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to the acquisitions of Dionex and Phadia may not materialize as expected. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.